Klott

Human coagulation factor VIII, the active ingredient in Klott, is a biologic presented as an injectable solution for intravenous use. It replaces deficient factor VIII to restore the intrinsic pathway of the coagulation cascade, providing hemostatic control for patients with hemophilia A.

GNH USA supplies Klott as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, specialized hemophilia treatment centres and clinics worldwide. The company ensures quality and regulatory compliance across EU and global markets, with cold‑chain logistics for biologic stability.

Klott is used to manage the intrinsic coagulation pathway disorder of hemophilia A.

Hemophilia A (severe): replaces deficient factor VIII to achieve hemostasis and reduce spontaneous bleeding. Hemophilia A (moderate): supports clot formation during minor injuries and routine activities. Surgical procedures in hemophilia A patients: provides peri‑operative factor VIII to maintain hemostasis during surgery.

Klott may be associated with a range of adverse reactions.

Common Side Effects: - Headache or mild fever following infusion. - Local infusion site reactions such as redness, swelling, or discomfort. - Nausea or mild arthralgia during treatment.

Serious or Rare Side Effects: - Development of neutralizing antibodies (inhibitors) against factor VIII. - Anaphylactic or severe allergic reactions, including rash and respiratory distress. - Thromboembolic events or excessive clot formation, particularly with high dosing. - Hemolysis or severe bleeding unrelated to therapy. - Potential transmission of viral agents despite rigorous screening.

When using Klott, several safety considerations should be observed.

Allergy assessment: screen for known hypersensitivity to factor VIII or any product component. Inhibitor monitoring: test for development of anti‑factor VIII antibodies during therapy. Thrombotic risk: avoid excessive dosing in patients with a history of thrombosis. Pregnancy and lactation: use only if benefits outweigh risks, under specialist guidance. Concomitant anticoagulants: adjust therapy and monitor coagulation parameters. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Klott can interact with other hemostatic agents and medications.

Major Interactions (Avoid): - Concurrent use of activated prothrombin complex concentrates (aPCC) may increase risk of thrombosis. - High‑dose recombinant factor VIIa combined with factor VIII can lead to uncontrolled clotting. - Use of antifibrinolytics (e.g., tranexamic acid) with high factor VIII levels may raise thrombotic risk.

Moderate Interactions (Monitor Closely): - Desmopressin (DDAVP) may augment endogenous factor VIII; monitor for additive effect. - Certain vaccines may cause bleeding at injection sites; observe local reactions. - CYP enzyme inducers have no known effect but clinical response should be monitored.